Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study

Pett, Sarah Lilian ; Amin, Janaki ; Horban, Andrejz ; Andrade-Villanueva, Jaime ; Losso, Marcelo ; Porteiro, Norma ; Madero, Juan Sierra ; Belloso, Waldo ; Tu, Elise ; Silk, David ; Kelleher, Anthony ; Harrigan, Richard ; Clark, Andrew ; Sugiura, Wataru ; Wolff, Marcelo ; Gill, John ; Gatell, Jose ; Fisher, Martin ; Clarke, Amanda ; Ruxrungtham, Kiat ; Prazuck, Thierry ; Kaiser, Rolf ; Wolley, Ian ; Arnaiz, Juan Alberto ; Cooper, David ; Rockstroh, Jürgen K. ; Mallon, Patrick ; Emery, Sean

Clinical infectious diseases, 2016-07, Vol.63 (1), p.122-132 [Periódico revisado por pares]

United States: Oxford University Press

Texto completo disponível